GRUPO DE ESTUDOS MULTICENTRICOS EM ONCO-HEMATOLOGIA

🇧🇷Brazil

Country: 🇧🇷Brazil

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation

Phase 3

Conditions: Multiple Myeloma Stage I

Interventions: Combination Product: Cyclo Thal Dex Daratumumab

First Posted Date: 2019-01-03

Last Posted Date: 2019-01-03

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 20

Registration Number: NCT03792620

Locations: 🇧🇷
CEHON - Centro de Hematologia e Oncologia da Bahia, Salvador, Bahia, Brazil

Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

Phase 3

Completed

Conditions: Multiple Myeloma
Effects of Chemotherapy

Interventions: Drug: Bortezomib, cyclophosphamide, thalidomide, dexamethasone

First Posted Date: 2018-01-18

Last Posted Date: 2018-01-18

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 311

Registration Number: NCT03402295

T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients

Conditions: T-cell Lymphoma
T-cell Lymphoma Adults
NK-Cell Lymphoma

First Posted Date: 2017-07-05

Last Posted Date: 2017-07-05

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 500

Registration Number: NCT03207789

Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients

Phase 4

Conditions: Oral Hemorrhage

Interventions: Drug: Aminocaproic acid
Other: Routine dental care
Drug: lidocaine and epinephrine
Drug: Paracetamol

First Posted Date: 2014-09-12

Last Posted Date: 2014-09-12

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 154

Registration Number: NCT02238288

Locations: 🇧🇷
Clementino Fraga Filho University Hospital, Rio de Janeiro, RJ, Brazil

Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease

Phase 3

Completed

Conditions: Graft vs Host Disease
Oral Manifestations

Interventions: Drug: Dexamethasone
Drug: Clobetasol

First Posted Date: 2012-10-03

Last Posted Date: 2012-10-03

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 28

Registration Number: NCT01699412

Locations: 🇧🇷
Hematology and Hemotherapy Center, Campinas, São Paulo, Brazil
🇧🇷
Clementino Fraga Filho University Hospital, Rio de Janeiro, Brazil

Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years

Phase 3

Conditions: Multiple Myeloma

Interventions: Drug: Thalidomide, Dexamethasone
Drug: Thalidomide, Melphalan, Prednisone
Drug: Thalidomide, Cyclophosphamide, Dexamethasone

First Posted Date: 2012-02-15

Last Posted Date: 2012-02-15

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 64

Registration Number: NCT01532856

Locations: 🇧🇷
Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
🇧🇷
Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil
🇧🇷
Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil

Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Thalidomide plus dexamethasone
Drug: Dexamethasone

First Posted Date: 2011-02-15

Last Posted Date: 2011-02-15

Lead Sponsor: Grupo de Estudos Multicentricos em Onco-Hematologia

Target Recruit Count: 213

Registration Number: NCT01296503

Locations: 🇧🇷
Universidade Estadual de Campinas, Campinas, São Paulo, Brazil
🇧🇷
Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil
🇧🇷
Universidade de São Paulo- Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil

and more 1 locations

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy